drugset / Trial / NCT00881569
Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017
NaSingle-groupOpen-labelTreatment
Summary
This is a study of CS-7017 designed to allow participants who completed participation in a clinical study of CS-7017 without experiencing disease progression or unacceptable toxicity to continue treatment with study drug. Participants who have not progressed while receiving CS-7017 will continue to benefit from longer administration of the agent.
Timeline
- Start
- 2009-03
- Primary completion
- 2011-03
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | efatutazone | Small molecule | 0.5 mg | Oral |
| Subject | efatutazone | Small molecule | 0.75 mg | Oral |
Indications
No indication recorded.